

Advances in Cancer Immunotherapy: A Focus on Nurses

Marianne Davies, DNP, ACNP-BC, APCNP®, FAAN
Smilow Cancer Hospital, Yale Cancer Center, Yale School of Nursing
New Haven, CT.

Beth Sandy, MSN, CRNP
Abramson Cancer Center, University of Pennsylvania
Philadelphia, PA

Disclosures

- Marianne Davies: no financial disclosures
- Beth Sandy discloses consulting or speaking fees for the following companies: Amgen, AstraZeneca, Jazz, Lilly, Janssen, Merck, Takeda.

Learning Objectives/Poll


Please rate your level of understanding on the below learning objectives in the poll on your screen.

- Describe the expanding landscape of immune checkpoint immunotherapy
- Identify available patient education resources for cancer immunotherapy immune-related adverse events.
- Distinguish the mechanisms of immune-related adverse reactions from cancer immunotherapy treatment
- Recognize and properly triage immune related adverse events related to cancer immunotherapy

It is recommended to hold ICI therapy for Grade 2 colitis. Grade 2 colitis is described as:

- A. Watery diarrhea
- B. 1-3 stools over baseline
- C. 4-6 stools over baseline
- D. Blood or mucus in the stool


Adaptive Immune System



Chen & Mellman. Immunity 2013


CTLA-4 and PD-1/PD-L1 Checkpoint Blockade

- **PRIMING PHASE:** Lymph Node





T-Cell Migration

Activation



- **EFFECTOR PHASE:** Peripheral Tissue




ICPI & Combinations

PD-1	PD-L1	CTLA-4	LAG-4
<ul style="list-style-type: none"> Nivolumab Pembrolizumab Cemiplimab Dostarlimab 	<ul style="list-style-type: none"> Atezolizumab Avelumab Durvalumab 	<ul style="list-style-type: none"> Ipilimumab Tremelimumab 	<ul style="list-style-type: none"> Relatimab
Approved Combinations			
<ul style="list-style-type: none"> Atezolizumab + bevacizumab Atezolizumab + chemotherapy +/- bevacizumab Avelumab + axitinib Durvalumab + chemotherapy Nivolumab + relatlimab 		<ul style="list-style-type: none"> Nivolumab + ipilimumab (+/-) limited chemotherapy Pembrolizumab + chemotherapy Pembrolizumab + axitinib Pembrolizumab + lenvatanib 	



Various Dosing Schedules: Based on disease and combinations

Approvals




Broad activity, but only subset of patients benefit: ~10-30%

- Merkel Cell
- Cutaneous Sq Cell
- Mesothelioma
- Cervical
- Esophageal
- Hodgkin's Lymphoma
- Primary mediastinal large-B cell Lymphoma
- Microsatellite instability High or mismatch repair deficient cancers


PD-L1 Expression: Defining the Level of Expression

- The expression of PD-L1 on tumor cells can be used to determine how well a patient might benefit from treatment with a PD-L1 inhibitor
- With PD-L1 testing, the dynamic nature of PD-L1 expression means that a “**cut-off**” is more appropriate to define the level of expression at which PD-L1 inhibitor treatment may be beneficial; tumors with PD-L1 expression higher than the cut-off are described as “PD-L1 high”




Rational for Combination Therapy

Chemotherapy: MOA-Priming




Immune Checkpoint: MOA



©2021 Cleveland Clinic

Adapted From: Chen & Mellman (2013).Immunity. 39




Immune Related Adverse Events (irAEs)

Organs Affected



May affect one or many organs
Concurrently or sequentially

Severity

Incidence/severity higher in anti-CTLA-4 agents
High grade AE to one class does not preclude safe administration to another class




Frequency of irAEs




Michot. 2016. Eur J Cancer 54:139

Immune-related Adverse Events (irAEs)

- Onset
 - Median onset is 5-12 weeks after initiation
 - Within days of first dose
 - After months of treatment
 - After discontinuation of therapy



Haanen JB, et al. Ann Oncol. 2017;28:iv119-iv142; Postow MA, et al. N Engl J Med. 2018;378:158-168;





Davies, M. & Duffield, E. (2017). Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. *ImmunoTargets and Therapy*. 6:51-71

Fatal irAEs


- Chemotherapy Fatalities: 1.4%
- ICB Fatality rates vary: 0.25%-1.1%

Cases and fatality rates



No. at risk

Ipilimumab	15	2	0	0	0	0	0
Anti-PD-1	34	11	5	2	2	2	0
Combination	6	0	0	0	0	0	0




Wang et al. 2018. JAMA Oncol. ; Nishijima et al. 2017. The Oncologist

irAEs Differ from Chemotherapy AEs

	Chemotherapy	Immunotherapy
Incidence (moderate/sever Aes)	Almost all patients	Majority Without
AE profile	Well described	Variable
Affected Organs	Few organs affected	Any Organ
Time Course	Well Established	Variable (even after end of tx)
	Predictable	Relatively Unpredictable

Any high-grade AEs



Lower total AEs* (67.6% vs 82.9%)
 Lower high-grade AEs* (11.4% vs 35.7%)
 Lower treatment discontinuation* (4.5% vs 11.1%)
 Lower treatment-related deaths (0.6% vs 1.4%)

*Statistically Significant

Nishijima et al 2017. The Oncologist

Preparing Patients for Therapy

- Patient Assessment
 - Evaluate for Auto-immune risks
 - Auto-immune diagnosis
 - Prior organ transplantation
 - Risk of graft loss
 - Medication reconciliation: including OTC and herbal
 - Immunosuppressants, immune stimulants, immune modulating
- Baseline review of systems
- Physical Examination
- Laboratory Evaluation
 - Complete blood count
 - Comprehensive Metabolic Panel
 - Thyroid Panel
 - Lipase
 - Troponin
 - CK



Preparing Patients for Therapy: Education

- How the immune system works
 - Potential IrAEs
 - Mechanism of IRAEs
 - Timing of onset
 - Signs & symptoms to report
 - Expectation of treatment
- Different AE profile than chemotherapy
 - Onset of the AE may help to diagnose etiology
 - irAEs can overlap and/or worsen with subsequent therapies
 - New irAEs can develop during subsequent therapies
 - Can be latent irAEs
- * Consider language, culture, literacy, timing and access

Patient Education Resources

NCCN National Comprehensive Cancer Network®

UNDERSTANDING IMMUNOTHERAPY SIDE EFFECTS

ASCO
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
A MEMBER OF THE SOCIETY OF MEDICAL ONCOLOGISTS

Immune checkpoint inhibitors (a type of immunotherapy) offer a promising new way to treat cancer for some patients. But these medicines can occasionally cause your immune system to attack normal organs and tissues in your body, affecting the way they work. Serious side effects typically occur in less than 5% of patients, but certain mild side effects can occur in up to 30% – 50% of patients.

Contact your health care professional right away if you think you may be experiencing...

- Brain inflammation (encephalitis)**
Fever, confusion; changes in mood or behavior; neck stiffness; seizures; extreme sensitivity to light.
- Eye problems**
Blurry or double vision or other vision problems; eye pain or redness.
- Lung problems (pneumonitis)**
New or worsening cough; shortness of breath.
- Liver problems (hepatitis)**
Yellowing of the skin or the whites of the eyes; severe nausea or vomiting; pain on the right side of the stomach; dark urine; bleeding or bruise more easily than normal.
- Intestinal problems (colitis)**
Diarrhea or more bowel movements than usual; stools I have blood or are dark, tarry, sticky; severe stomach-area pain.
- Nerve problems**
Numbness or tingling in hand or feet; unusual weakness in legs, arms, or face.
- Hormone gland problems (especially the thyroid, pituitary, adrenal glands, pancreas)**
Persistent or unusual headaches; extreme tiredness; weight loss or gain; rapid heartbeat; increased sweating; hair loss; constipation; dizziness or fainting.
- Kidney problems**
Decrease in the amount of urine; blood in the urine.
- Skin problems**
Rashes; itching; blistering; painful sores or ulcers.
- Joint or muscle problems**
Severe or persistent muscle or joint pain; severe muscle weakness.

© National Comprehensive Cancer Network® (NCCN) 2018. All Rights Reserved.

NCCN National Comprehensive Cancer Network®

WHAT IS IMMUNOTHERAPY?

- ✓ Immune checkpoint inhibitors are a new type of cancer medicine called immunotherapy.
- ✓ These medicines are designed to work with your immune system to treat certain types of cancer.
- ✓ Immunotherapy works differently than traditional chemotherapy and can cause different kinds of side effects.
- ✓ It is important to be aware of possible side effects and contact your health care professional right away if you experience any problems.

Current FDA-Approved Immune Checkpoint Inhibitors

- Atezolizumab (Tecentriq®)
- Avelumab (Bavencor®)
- Durvalumab (ImmuPep®)
- Ipilimumab (Yervoy®)
- Nivolumab (Opdivo®)
- Pembrolizumab (Keytruda®)

Did you Know?

- No matter where your cancer began, side effects from immunotherapy can affect your whole body.
- Side effects may appear shortly after beginning treatment, within the first couple of months, or even after you finish treatment.
- Because many of these side effects can occur from other causes that would be treated differently, make sure your doctor knows you are or were on immunotherapy.
- You may be more likely to experience side effects if you are taking more than one kind of immunotherapy or immunotherapy combined with other types of cancer medicines.
- Many of these immune side effects are treatable. Your doctor may prescribe corticosteroids or other medications to help manage any problems.
- Rare but serious side effects can lead to death, especially if left untreated.

This information does not replace the expertise and clinical judgment of the clinician. If you think you are experiencing these symptoms, call your doctor today.

NCCN.org – For Clinicians | **NCCN.org/patients** – For Patients
275 Commerce Drive • Suite 300 • Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280

Checkpoint Inhibitors IMMUNOTHERAPY

HOW THEY FUNCTION

- Checkpoint inhibitors block the action of immune system checkpoints that slow or stop the immune system (e.g., PD-1, PD-L1, CTLA-4).
- Checkpoint inhibitors “take the brakes off” of the immune system, allowing it to stay in overdrive and survey for cancer cells.

WHEN THEY’RE OFFERED

- Most approved indications are for after failed front-line chemotherapy.
- Combinations of different checkpoint inhibitor agents are showing promise.

WHICH CANCERS DO THEY TREAT?

Current approvals are for multiple solid organ malignancies such as metastatic melanoma, renal cell carcinoma, bladder cancer, non-small cell lung cancer, and gynecologic cancers as well as lymphoma in the hematologic setting.

PATIENT EDUCATION POINTS

- Patients need to report any new symptom as it could be the development of an immune-related adverse event; early recognition and treatment is critical to successful management.
- Treatment response may not be seen immediately, but may take weeks to months for tumors to show signs of shrinking.

POTENTIAL ADVERSE REACTIONS & SIDE EFFECTS

- Fatigue
- Infusion Reactions
- Immune-Related Adverse Events: colitis, dermatitis, pneumonitis, endocrinopathies
- Expect to see diarrhea, abdominal cramping, skin changes/irritation, cough, lab abnormalities

MORE RESOURCES

SPEED TALK CHECKPOINT INHIBITORS IN 5 MINUTES
<https://youtu.be/M2YTDw6dc>

NETWORK WITH COLLEAGUES IN THE ONCOIMMUNOTHERAPY COMMUNITY
oncoimmunotherapy.com

AMERICAN SOCIETY OF CLINICAL ONCOLOGY
www.asco.org/supplemental-care-guidelines

Copyright © 2018 Oncology Nursing Society. All rights reserved.

AIM Immunotherapy Action Plan

YOUR KEYTRUDA® (pembrolizumab) ACTION PLAN

Immunotherapy can cause side effects. It's important to know what to look for and when to call your doctor.

TAKING THE MEDICATION

How to take your medication and what to expect.

LUNG AND BREATHING PROBLEMS

What to watch for and when to call your doctor.

OTHER SYMPTOMS TO LOOK OUT FOR

Diarrhea, skin rash, joint pain, and other symptoms.

RESOURCES

Additional information and support resources.

IMMUNOTHERAPY WALLET ID CARD

PATIENT NAME: _____
EMERGENCY CONTACT NAME: _____
ONCOLOGY TEAM PRIMARY CONTACT: _____
CANCER DIAGNOSIS: _____
ONCOLOGY PROVIDER NAME: _____ AM to _____ PM
PROVIDER HOURS: MON, THRU FRI. _____ AFTER-HOURS TEL: _____
TEL: _____


This patient is receiving IMMUNOTHERAPY for cancer treatment. Side effects may differ from standard chemotherapy but with PROMPT recognition and management, most side effects are treatable. Please contact the oncology provider's office for assistance in managing immune-related adverse events.

Contact your oncology provider's office if you experience any of these symptoms:

- Trouble breathing, wheezing, coughing, or chest pain
- Fever (oral temperature greater than 101°F)
- Decreased urination, blood in urine, or swollen ankles
- Severe or worsening muscle pain or weakness
- Joint stiffness (unable to perform regular daily activities)
- Severe headaches, dizziness, confusion, change in vision, or eye pain
- Any new or worsening symptoms

AIM Immunotherapy Action Plan

Patient Education Resources



ASCO[®] answers Understanding Immunotherapy

What is immunotherapy?

Immunotherapy is a treatment using medication designed to boost the body's natural defenses to fight cancer. It uses materials made by the body or in a laboratory to boost, target, or restore a person's immune system. The immune system is a network of cells, tissues, and organs that work together to protect the body from infection.


Certain types of immunotherapy attack cancer or slow its spread to other parts of the body. Other types make it easier for the immune system to destroy cancer cells. Your doctor may recommend immunotherapy after or at the same time as another treatment, such as chemotherapy. Or immunotherapy may be used by itself.

What are the types of immunotherapy?

There are several types of immunotherapy, including monoclonal antibodies, cancer vaccines, oncolytic virus therapy, T-cell therapy, and non-specific immunotherapies. Monoclonal antibodies act like the antibodies your body makes naturally to fight harmful substances. They are designed to target a specific protein in cancer cells. Most of the new immunotherapies are monoclonal antibodies. These may also be called checkpoint inhibitors. Checkpoint inhibitors are a specific type of cancer drug that allows the immune system to destroy cancer cells. Some types of immunotherapy may deliver small radiation doses or other cancer drugs to the cancer cell. Cancer vaccines that treat cancer are still uncommon, but many are being studied in clinical trials. A cancer vaccine is a way of exposing the immune system to an antigen. This triggers the immune system to find and destroy that antigen or related materials. Oncolytic virus therapy uses viruses that have been changed in a laboratory to destroy cancer cells. In T-cell therapy, the doctor removes specific immune cells, called T cells, from your blood. Then, a laboratory adds specific proteins called receptors to the cells. The receptors allow those T cells to recognize cancer cells. The changed T cells are put back into your body. Once there, they find and destroy cancer cells. Examples of non-specific immunotherapies include interferons and interleukins.

What are the side effects of immunotherapy?

Immunotherapy is different from traditional chemotherapy and can cause different side effects. And different immunotherapies cause different side effects. Each person's experience also depends on the type of cancer and its location, treatment dose, and your overall health. Preventing and managing side effects is a major focus of your health care team. Talk with them right away about any changes in how you feel, even if you don't think the side effect is serious. Side effects from monoclonal antibody treatment can include rashes, low blood pressure, and flu-like symptoms, such as fever, chills, headache, weakness, and vomiting. Non-specific immunotherapies can cause flu-like symptoms, as well as an increased risk of infection, rashes, and thinning hair. Other types of side effects are possible, too. Ask your doctor what side effects you may have based on the specific medicine(s) recommended for you. Most side effects go away after treatment, although some long-term side effects may occur months or even years after treatment. Learn more about managing side effects at www.cancer.net/sideeffectsimmunotherapy.



Questions to ask the health care team

Regular communication is important for making informed decisions about your health care. It can be helpful to bring someone along to your appointments to take notes. Consider asking your health care team the following questions:

- ▶ What type of immunotherapy do you recommend and why?
- ▶ What is the goal of this treatment? To destroy cancer cells? To slow down the spread of cancer to other parts of the body?
- ▶ What immunotherapy clinical trials are available for me? Where are they located, and how do I find out more about them?
- ▶ Will immunotherapy be my only treatment or will other treatments be a part of my treatment plan?
- ▶ How will the treatment be given?
- ▶ How often will I receive this treatment? How long does each treatment session take?
- ▶ Where will I receive treatment?
- ▶ What will I experience when I receive this treatment?
- ▶ What can I do to get ready for this treatment?
- ▶ What are the possible short-term and long-term side effects of this treatment?
- ▶ How can those side effects be avoided or managed?
- ▶ How soon should I let you know about changes in how I'm feeling?
- ▶ How will this treatment affect my daily life? Will I be able to work, exercise, and perform my usual activities?
- ▶ If I'm worried about managing the costs of cancer care, who can help me?
- ▶ If I have a question or problem, who should I call?

Find more questions to ask the health care team at www.cancer.net/immunotherapy. For a digital list of questions, download Cancer.Net's free mobile app at www.cancer.net/app.

This fact sheet was developed and is © 2021 American Society of Clinical Oncology, Inc. (ASCO). All rights reserved worldwide. No sponsor was involved in the development of the content. The mention of any company, product, service, or therapy does not constitute an endorsement of any kind by ASCO or Conquer Cancer®, the ASCO Foundation. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the fact sheet or any errors or omissions. Information in ASCO's patient education materials is not intended as medical advice or as a substitute for medical advice. Patients with health care-related questions should call or see their physician or other health care provider promptly and should not disregard professional medical advice, or delay seeking it, because of information encountered here. ASCO believes that all treatment decisions should be made between patients and their doctors. Advances in the diagnosis, treatment, and prevention of cancer occur regularly. For more information, visit Cancer.Net (www.cancer.net).

Health Care Professionals: To order more printed copies, please call 888-273-3508 or visit www.cancer.net/estore.

Words to know

Antibodies: Proteins that fight infection.

Antigens: Harmful substances that cause your body to make antibodies.

Biologic therapy: Another name for immunotherapy.

Clinical trial: A research study that tests a new treatment or drug.

Intravenous immunotherapy: Medication given directly into a vein.

Medical oncologist: A doctor who specializes in treating cancer with medication.

Oncolytic virus therapy: A treatment that uses genetically modified viruses to destroy cancer cells.

Oral immunotherapy: Medication swallowed as a pill, capsule, or liquid.

Radiolimmunotherapy: An immunotherapy treatment that delivers radiation directly to cancer cells.

Side effects: Problems that happen during or after treatment. These could be from the cancer or how the treatment affects your body.


Targeted therapy: Treatment that targets a cancer's specific genes, proteins, or the tissue environment that contributes to cancer.

T-cell therapy: A treatment that modifies a patient's own T cells to destroy cancer cells.


MADE AVAILABLE THROUGH

Professional Resources



- All staff must be educated on triage
- Educate patients on the telephone triage process
- Provides tool to distinguish patients who can be treated at home and those that need formal evaluation or hospitalization
- Early identification of symptoms may minimize severity of IRAE



Professional Resources Clinical Practice Guidelines (CPGs)




SITC Professional Resources



- Acute Leukemia
- Breast Cancer
- Gastrointestinal
- ICI-related adverse events
- Head & Neck Squamous Cell
- Lung & Mesothelioma
- Gynecologic
- Hepatocellular
- Lymphoma
- Melanoma
- Multiple Myeloma
- Renal Cell
- Prostate
- Urothelial
- Non-Melanoma Skin


General Management of irAEs.



Davies M (2023); Adapted from NCCN, SITC, & ASCO Guidelines

Why do IRAE's happen to patients on immunotherapy?

- Explain to patients it is due to overactive T-cell activity
 - Can mimick auto-immune diseases
- May help them understand importance to call
- Educate patients on the common areas to be affected:
 - In NSCLC, rates of pneumonitis tend to be higher, 7-13%
 - Rates of colitis higher in CTLA-4 containing regimens.



Zhai X, Zhang J, Tian Y, et al. Cancer Biol Med (2020). 17(3):599-611; IRAE- Immune-related adverse event


Early Detection Key

- If we can detect these IRAE's earlier, (grade 1 or 2), and manage them, better chance to stay on therapy and less risk of severe toxicity to patients.
- Once toxicity is grade 3, and definitely for grade 4, requires permanent discontinuation of immunotherapy.
- For patients receiving immunotherapy, consider all reported symptoms or side effects as related to immunotherapy until you can reasonably determine it is not. (Anything on the body can be inflamed)

Pneumonitis: What you will find, when to bring them in?

- Sometimes called ILD
- Inflammation of the pulmonary tissues from T-cell assault
- Symptoms are acute onset
SOB over 1-2 days; dry irritating cough; hypoxia

After 1 treatment with Pembrolizumab



ILD= Interstitial Lung Disease

Pneumonitis:

- Rates of pneumonitis are higher in patients with lung cancer 13-19% as opposed to 3-5% rates reported across other disease sites.
- Can occur at any time
- Differentials: PE, Pleural effusion, Pneumonia
- Must get a CT chest to evaluate
- Treatment promptly with prednisone at around 1-2mg/kg and taper slowly over 4-6 weeks. It is good to get a repeat CT chest prior to resuming immunotherapy to be sure the pneumonitis has resolved/improved.

Suresh K, et al. J Thoracic Oncol. 2018;13(12) 1930-1939. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf; ICI_PULM-1

Colitis: How to evaluate, when to bring them in, what is “diarrhea” vs “colitis”

- First question: how many stools per day over your baseline?
 - This establishes your grading of diarrhea
- Workup:
 - Do you need to confirm with diagnostics when symptoms present?
 - CT abdomen can show pancolitis in more severe cases
 - Do not recommend scope at first, especially when inflamed bowel
 - Fecal calprotectin (and other r/o stool specimens if/when indicated)

Diarrhea	Description
Grade 1	<4 stools over baseline
Grade 2	4-6 stools over baseline
Grade 3	> 7 stools over baseline
Grade 4	Life threatening

Colitis	Description
Grade 1	Asymptomatic; diagnostic findings only
Grade 2	Abdominal pain; blood or mucus in the stool
Grade 3	Severe abdominal pain; peritoneal signs
Grade 4	Life Threatening

Colitis/Diarrhea:

- Diarrhea vs Colitis occurs in:
 - 44% and 16% in combined ICI regimens, respectively
 - 11% and 1% in PD-1/L1 regimens, respectively
- Colitis is more serious and diarrhea can lead to colitis
- Treatment is with high dose prednisone, again 1-2mg/kg, consider IV
- Upon resumption of the immunotherapy, about 34% experienced recurrence of colitis
- Consider infliximab or Vedolizumab if not responsive to prednisone

Nephritis/Hepatitis: The paper toxicity?!

Nephritis

- Usually not symptomatic initially
- Sharp rise in Creat;
- Not gradual

12/29/2022 9:32:00 AM	Final	Creatinine	1.65H	mg/dL	0.64-1.27
12/12/2022 10:13:00 AM	Final	Creatinine	1.93H	mg/dL	0.64-1.27
12/12/2022 10:13:00 AM	Final	Creatinine	1.91H	mg/dL	0.64-1.27
11/28/2022 1:41:00 PM	Final	Creatinine	2.72H	mg/dL	0.64-1.27
11/28/2022 1:41:00 PM	Final	Creatinine	2.72H	mg/dL	0.64-1.27
11/25/2022 4:14:00 AM	Final	Creatinine	4.02H	mg/dL	0.64-1.27
11/24/2022 5:02:00 AM	Final	Creatinine	4.37H	mg/dL	0.64-1.27
11/23/2022 5:01:00 AM	Final	Creatinine	4.78H	mg/dL	0.64-1.27
11/22/2022 12:17:00 PM	Final	Creatinine	5.33H	mg/dL	0.64-1.27
11/22/2022 12:17:00 PM	Final	Creatinine	5.4H	mg/dL	0.6-1.0
11/21/2022 3:13:00 PM	Final	Creatinine	5.82H	mg/dL	0.64-1.27

Hepatitis

- Usually not symptomatic initially
- Sharp rise in LFT's;
- Not gradual

Collected Date/Time	Sts	Test	Value	Units	Range
12/21/2021 1:59:00 PM	Final	ALT	25	U/L	17-63
12/13/2021 10:55:00 AM	Final	ALT	40	U/L	17-63
11/30/2021 9:00:00 AM	Final	ALT	15L	U/L	17-63
11/5/2021 11:06:00 AM	Final	ALT	24	U/L	17-63
10/10/2021 3:04:00 AM	Final	ALT	147H	U/L	17-63
10/9/2021 10:34:00 AM	Final	ALT	180H	U/L	17-63
10/5/2021 1:46:00 PM	Final	ALT	212H	U/L	17-63
9/14/2021 1:14:00 PM	Final	ALT	23	U/L	17-63
8/30/2021 1:42:00 PM	Final	ALT	37	U/L	17-63
8/25/2021 10:04:00 AM	Final	ALT	52	U/L	17-63
8/17/2021 1:08:00 PM	Final	ALT	23	U/L	17-63
7/27/2021 2:09:00 PM	Final	ALT	34	U/L	17-63

Nephritis/Hepatitis: The paper toxicity?!

- Usually not something patients will call in with since not usually “feeling” it
- Don’t forget to be checking these labs each with each treatment, can happen at any time
- Prompt treatment with prednisone; IV hydration likely in order for the nephritis cases
- Recheck labs in a week or less, follow up quickly to be sure steroids are helping

Hypo/Hyperthyroidism: Paper toxicity versus Symptomatic

Hypothyroidism

- TSH is high, T4 (thyroxine) is low
- Most times not symptomatic, but can be: Sluggish, gaining weight, sensitivity to cold, slow movements/thoughts
- Treatment is replacement of thyroid hormone with levothyroxine
- If asymptomatic, can wait till TSH is over 10 to initiate therapy.

Hyperthyroidism

- TSH is low, T4 is high
- usually just watch it and they become hypothyroid eventually
- If symptomatic: weight loss, jittery, hyperactive, tachycardia
- endocrine consult, consider treating symptoms such as tachycardia, etc.


https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf; ICI_ENDO-2

Hypophysitis/Adrenal Insufficiency

- The pituitary gland becomes inflamed due to overactive T-cell activity
- Thus, in turn, it does not send signals to the adrenal glands to produce cortisol (causing secondary AI). Can also contribute to hypothyroidism.
 - 6.4% in combination ICI
 - 3.2% anti-CTLA4
 - 1-5% in PD-1/PD-L1 therapy*
- Symptoms: very, very fatigued, hypotensive, anorexia
- Labs: check cortisol (9am preferred...); ACTH can be useful as well. Put the cortisol level into context.
- MRI brain (with pituitary cuts)- sometimes will show enlarged pituitary gland.
- Consult with Endocrine, can be tricky

Hypophysitis/Adrenal Insufficiency

- Bring patient in, get labs, likely needs IV hydration, stop BP meds if hypotensive
- Replace cortisol with oral (or acutely IV) hydrocortisone.
- Corticosteroids only if inflammation is causing neurologic issues.



Mahzari M, et al. *Clinical Medicine Insights: Endocrinology and Diabetes*. 2015;8 21–28 doi:10.4137/CMED.S22469

Dermatitis:

- Overactive T-cells cause skin eruptions.
- Mostly mild rashes
- More common with anti-CTLA4 regimens and in patients with melanoma
- Grading is hard, there are 2 categories, bullous dermatitis and Rash acneiform

Rash (acneiform)	Description
Grade 1	<10% BSA
Grade 2	10-30% BSA
Grade 3	> 30% BSA
Grade 4	Life threatening

Bullous Dermatitis	Description
Grade 1	<10% BSA blisters
Grade 2	10-30% BSA blisters
Grade 3	> 30% BSA blisters
Grade 4	Life threatening

Dermatitis:

- More severe reactions can occur
- Grade 3 sometimes can be rechallenged, but not cases of SJS or BP
- Use of topical steroids is common, even for grade 2 rashes. Often will continue immunotherapy for grade 1 and 2 if patient is not bothered by the rash
- Rashes can be of all sorts: eczema; psoriatic; papular; pustular; red/edema



SJS: Steven-Johnson Syndrome; BP: Bullous Pemphigoid

It is recommended to hold ICI therapy for Grade 2 colitis. Grade 2 colitis is described as:

- A. Watery diarrhea
- B. 1-3 stools over baseline
- C. 4-6 stools over baseline
- D. Blood or mucus in the stool

Learning Objectives/Poll

Please rate your level of understanding on the below learning objectives in the poll on your screen.

- Describe the expanding landscape of immune checkpoint immunotherapy
- Identify available patient education resources for cancer immunotherapy immune-related adverse events.
- Distinguish the mechanisms of immune-related adverse reactions from cancer immunotherapy treatment
- Recognize and properly triage immune related adverse events related to cancer immunotherapy